Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
As more people have their genomes sequenced, some researchers seek to enable mechanisms for genome data donation, similar to organ and tissue donation.
With a two-stage atrial fibrillation GWAS, researchers took a crack at untangling the pathways, regulatory features, and tissue types contributing to the heart condition.
A University of Alabama at Birmingham-led team has found that mutations within five NF1 codons are linked to an increased likelihood of severe neurofibromatosis symptoms.
The newly launched LunaDNA hopes that its community model of compensating individuals for contributing genomic and health information will lead to better research.
The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
The firm said the charges, related to deferred tax assets, revaluation of deferred tax liabilities, and other tax provisions, won't affect its adjusted EPS.
The two companies have signed a new master collaboration agreement under which HTG will develop custom assays for use in earlier stages of Merck's drug development process.
OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.
Marcus Schabacker, a board-certified anesthesiologist and intensivist, has been named CEO and president of ECRI Institute, a health services research organization with an interest in genetic testing. Schabacker, who has 18 years of leadership experience in the medical device and pharmaceutical industries, recently served as chief scientific officer of Baxter. He previously helped Nelson Mandela rebuild South Africa's rural health system in the post-Apartheid era. Schabaker will replace Jeffrey Lerner, who is retiring Dec. 31 after 16 years as ECRI president and CEO.